Development of a homogenous RSV neutralisation assay on the mirrorball fluorescence cytometer


Application notes


Human respiratory syncytial virus (RSV) is a syncytial virus that can cause serious respiratory tract infections, especially in infants and young children[1]. To date there is no licensed vaccine against RSV infection and the only preventative treatment option is the neutralising anitbody palivizumab, which is given to high risk infants by passive administration[2]. Therefore there is a strong drive to identify novel RSV neutralising antibodies for therapeutic/ preventative applications. Here we present the development and implementation of a simple RSV neutralisation assay on TTP Labtech’s mirrorball fluorescence cytometer.